<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147793">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01650987</url>
  </required_header>
  <id_info>
    <org_study_id>SEXUTOX</org_study_id>
    <nct_id>NCT01650987</nct_id>
  </id_info>
  <brief_title>Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function</brief_title>
  <acronym>SEXUTOX</acronym>
  <official_title>Prospective Observational Study of Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the toxicities of cervix and corpus uteri carcinomas treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Toxicities including on sexual function</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>According to Lent-Soma, NCICTC-AE v3.0, Franco-Italian Glossary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the various scales of toxicity</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare the various scales of toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the sexual behavior modifications</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>According to a questionnaire and a personal discussion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specify correlation modifications of sexual behavior</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specify the existence of a correlation between toxicities included modifications and sexual behavior modifications</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Corpus Uteri Carcinoma</condition>
  <arm_group>
    <arm_group_label>Col 1</arm_group_label>
    <description>Patient with uterus adenocarcinoma, treated by surgery, then surveillance without complementary treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Col 2</arm_group_label>
    <description>Patient with uterus adenocarcinoma, treated by surgery then adjuvant radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Col 3</arm_group_label>
    <description>patient with uterus adenocarcinoma, treated by surgery then curietherapy of vaginal dome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial 4</arm_group_label>
    <description>patient with cervix carcinoma stage IA2 to IIB, treated by surgery only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endometrial 5</arm_group_label>
    <description>patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endometrial 6</arm_group_label>
    <description>patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy and radiotherapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women with a corpus uteri carcinoma, without metastasis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients whose treatment is provided to Centre Oscar Lambret

          -  With a corpus uteri adenocarcinoma, no metastatic, treated by:

               -  Surgery and observation without complementary treatment or

               -  Surgery and adjuvant radiotherapy or

               -  Surgery and curietherapy of vaginal dome

          -  With a cervix carcinoma, stade IA2 to IIB proximal, treated by :

               -  External radiochemotherapy and curietherapy or

               -  Only surgery or

               -  Pre-surgical curietherapy and surgery

          -  Age &gt; 18 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe NICKERS, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oscar Lambret Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe NICKERS, PhD</last_name>
    <email>p-nickers@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>VENDEL Yvette, CRA sponsor</last_name>
    <phone>03 20 29 59 40</phone>
    <email>y-vendel@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe NICKERS, PhD</last_name>
      <email>p-nickers@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Eric LARTIGAU, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard CASTELAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric LEBLANC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice NARDUCCI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne LESOIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick CHEVALIER-PLACE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 26, 2012</lastchanged_date>
  <firstreceived_date>July 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carcinoma</keyword>
  <keyword>uterus</keyword>
  <keyword>Not metastatic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
